StreetInsider.com News Articles

Form 4 MANNKIND CORP For: Mar 10 Filed by: Castagna Michael

Tue, 10 Mar 2026 21:30:00 -0400

si-local-file:///var/storage/secattach/20260310/26141421.html

Form 4 MANNKIND CORP For: Mar 10 Filed by: Castagna Michael

Tue, 10 Mar 2026 21:30:00 -0400

si-local-file:///var/storage/secattach/20260310/26141421.html

MannKind to present Afrezza pediatric diabetes data at ATTD 2026

Mon, 09 Mar 2026 09:05:15 -0400

MannKind Corporation (NASDAQ: MNKD) announced it will present new clinical and real-world data on Afrezza inhaled insulin at the Advanced Technologies & Treatments for Diabetes Conference from March 11-14, 2026, in Barcelona, Spain.

The presentations will include two oral sessions and one poster covering dosing patterns in youth and post-meal glucose management strategies using inhaled insulin in adults and children with type 1 diabetes. One oral presentation will compare Afrezza's effectiveness for post-meal glucose control across multiple clinical studies, while another will highlight data from the INHALE-1 study in pediatric patients with type 1 or type 2 diabetes.

The INHALE-1 study examined

MannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026

Mon, 09 Mar 2026 09:05:00 -0400

Presentations highlight real‑world dosing and titration patterns in youth, and post‑prandial glucose management strategies using inhaled insulin in both adults and youth with T1D
Data to be featured across oral and poster sessions at the Advanced Technologies & Treatments for Diabetes Conference (ATTD)
PDUFA target action date for Afrezza in children and adolescents living with type 1 or type 2 diabetes set for May 29, 2026

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions

MannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026

Mon, 09 Mar 2026 09:05:00 -0400

Presentations highlight real‑world dosing and titration patterns in youth, and post‑prandial glucose management strategies using inhaled insulin in both adults and youth with T1D
Data to be featured across oral and poster sessions at the Advanced Technologies & Treatments for Diabetes Conference (ATTD)
PDUFA target action date for Afrezza in children and adolescents living with type 1 or type 2 diabetes set for May 29, 2026

MannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026

Mon, 09 Mar 2026 09:05:00 -0400

Presentations highlight real‑world dosing and titration patterns in youth, and post‑prandial glucose management strategies using inhaled insulin in both adults and youth with T1D
Data to be featured across oral and poster sessions at the Advanced Technologies & Treatments for Diabetes Conference (ATTD)
PDUFA target action date for Afrezza in children and adolescents living with type 1 or type 2 diabetes set for May 29, 2026

MannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026

Mon, 09 Mar 2026 09:05:00 -0400

Presentations highlight real‑world dosing and titration patterns in youth, and post‑prandial glucose management strategies using inhaled insulin in both adults and youth with T1D
Data to be featured across oral and poster sessions at the Advanced Technologies & Treatments for Diabetes Conference (ATTD)
PDUFA target action date for Afrezza in children and adolescents living with type 1 or type 2 diabetes set for May 29, 2026

MannKind settles $36.3 million convertible notes with cash and stock

Thu, 05 Mar 2026 16:30:23 -0400

MannKind Corporation (NASDAQ: MNKD) settled $36.3 million in convertible senior notes on March 4, 2026, the company announced. The 2.50% convertible senior notes were tendered for conversion prior to their March 1, 2026 maturity date.

The settlement consisted of $35.5 million in cash and 569,023 shares of MannKind common stock. All remaining notes in this series were converted as part of the transaction.

MannKind is a biopharmaceutical company focused on cardiometabolic and orphan lung diseases, developing treatments for diabetes, pulmonary hypertension, and fluid overload conditions. The company specializes in drug-device combination therapies.

The information is based on a company press release statement.

MannKind Announces Settlement of Convertible Senior Notes

Thu, 05 Mar 2026 16:30:00 -0400

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced the settlement of the remaining $36.3 million aggregate principal amount of 2.50% convertible senior notes, all of which were tendered for conversion prior to the maturity date of March 1, 2026. The settlement was made on March 4, 2026, with $35.5 million in cash and 569,023 shares of MannKind common stock.

About MannKind
MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we

MannKind Announces Settlement of Convertible Senior Notes

Thu, 05 Mar 2026 16:30:00 -0400

MannKind Announces Settlement of Convertible Senior Notes

Thu, 05 Mar 2026 16:30:00 -0400

MannKind Announces Settlement of Convertible Senior Notes

Thu, 05 Mar 2026 16:30:00 -0400

MannKind to Participate in Upcoming Investor Conferences

Wed, 04 Mar 2026 09:00:00 -0400

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), announced today its attendance at two upcoming investor conferences, at which MannKind’s Chief Executive Officer, Michael Castagna, PharmD, and Chief Financial Officer, Chris Prentiss will participate in fireside chats and in 1x1 meetings with investors.

Leerink Partners 2026 Global Healthcare Conference in Miami
Tuesday, March 10, 3:40 p.m. ET

Barclays 28^th Annual Global Healthcare Conference in Miami
Wednesday, March 11, 1:00 p.m. ET

Links to the live audio webcast of the sessions will be available on MannKind Corporation’s website at: https://investors.mannkindcorp.com/events-and-presentations. Recorded

MannKind to Participate in Upcoming Investor Conferences

Wed, 04 Mar 2026 09:00:00 -0400

Leerink Partners 2026 Global Healthcare Conference in Miami
Tuesday, March 10, 3:40 p.m. ET

Barclays 28^th Annual Global Healthcare Conference in Miami
Wednesday, March 11, 1:00 p.m. ET

Links to the live audio webcast of the sessions will be available on MannKind Corporation’s website at: https://investors.mannkindcorp.com/events-and-presentations. Recorded

MannKind to Participate in Upcoming Investor Conferences

Wed, 04 Mar 2026 09:00:00 -0400

Leerink Partners 2026 Global Healthcare Conference in Miami
Tuesday, March 10, 3:40 p.m. ET

Barclays 28^th Annual Global Healthcare Conference in Miami
Wednesday, March 11, 1:00 p.m. ET

Links to the live audio webcast of the sessions will be available on MannKind Corporation’s website at: https://investors.mannkindcorp.com/events-and-presentations. Recorded

MannKind to Participate in Upcoming Investor Conferences

Wed, 04 Mar 2026 09:00:00 -0400

Leerink Partners 2026 Global Healthcare Conference in Miami
Tuesday, March 10, 3:40 p.m. ET

Barclays 28^th Annual Global Healthcare Conference in Miami
Wednesday, March 11, 1:00 p.m. ET

Links to the live audio webcast of the sessions will be available on MannKind Corporation’s website at: https://investors.mannkindcorp.com/events-and-presentations. Recorded

Form 4 MANNKIND CORP For: Mar 01 Filed by: Shannon James Samuel